Rupatadine: A new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist - A review of pharmacological profile and clinical management of allergic rhinitis

Drugs of Today

Volumn 39, Issue 6, 2003, Pages 451-468

  Izquierdo, Iñaki ^a   Merlos, Manuel ^a   García Rafanell, Julián ^a,b  

^a Research and Devmt Sci Area   (Spain)

^b Grupo Uriach   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; APAFANT; CALCIMYCIN; CALCIUM IONOPHORE; CETIRIZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; COMPOUND 48-80; CYTOCHROME P450 INHIBITOR; DIPHENHYDRAMINE; EBASTINE; ERYTHROMYCIN; FEXOFENADINE; HISTAMINE H1 RECEPTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; HYDROXYZINE; KETOCONAZOLE; LORATADINE; MIZOLASTINE; RUPATADINE; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; THROMBOCYTE ACTIVATING FACTOR RECEPTOR;

ALLERGIC RHINITIS; ALLERGY; AREA UNDER THE CURVE; ASTHENIA; CARDIOTOXICITY; CHEMOTAXIS; CONCENTRATION RESPONSE; DOG; DOSE TIME EFFECT RELATION; DRUG ANTAGONISM; DRUG CROSS REACTIVITY; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; ELDERLY CARE; EMBRYO DEVELOPMENT; FATIGUE; HEADACHE; HEART ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HISTAMINE RELEASE; HUMAN; IC 50; IN VITRO STUDY; INFLAMMATION; LONG QT SYNDROME; MAST CELL DEGRANULATION; NASAL PRURITUS; OCULAR PRURITUS; PERENNIAL RHINITIS; PHARYNX DISEASE; QT INTERVAL; RECEPTOR BLOCKING; REVIEW; RHINORRHEA; SEASONAL AFFECTIVE DISORDER; SEDATION; SIDE EFFECT; SNEEZING; SOMNOLENCE; SYMPTOMATOLOGY; TOXICOKINETICS; XEROSTOMIA;

ANIMALS; CLINICAL TRIALS; CYPROHEPTADINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HISTAMINE H1 ANTAGONISTS; HUMANS; PLATELET ACTIVATING FACTOR; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL;

EID: 0041431065     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2003.39.6.799450     Document Type: Review

References (50)

1. Skoner, D.P. Allergic rhinitis: Definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 2001, 108 (Suppl.): S2-S8.
2. Boulay, M.E., Boulet, L.P. The relationships between atopy, rhinitis and asthma: Pathophysiological considerations. Curr Opin Allergy Clin Immunol 2003, 3: 51-5.
3. Bousquet, J., Van Cauwenberge, P., Khaltaev, N., Aria Workshop Group and World Health Organization. Allergic rhinitis and its impact on asthma. 2001, 108 (Suppl. 5): S147-S334.
4. Howarth, P.H. Cellular basis for allergic rhinitis. Allergy 1995, 50 (Suppl. 23): 6-10.
5. Eiser, N.M., Mills, J., Snashall, P.D., Guz, A. Clin Sci 1981, 60: 363-70.
6. Demopoulos, C.A., Pinckard, R.N., Hanahan, D.J. Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active componet (a new class of lipid chemical mediators). J Biol Chem 1979, 254: 9355-8.
7. Yamada, Y., Yokota, M. Roles of plasma platelet-activating factor acetylhydrolase in allergic, inflamatory, and atherosclerotic diseases. Jpn Circ J 1998, 62: 328-35.
8. Evans, T.W., Rogers, D.F., Aursudkij, B., Chung, K.F., Barnes, P.J. Inflammatory mediators involved in antigen-induced airway microvascular leakage in guinea pigs. Am Rev Respir Dis 1988, 138: 395-9.
9. Labrakis-Lazanas, K., Lazanas, M., Koussissis, S., Tournis, S., Demopoulos, J. Evidence of PAF-acether metabolic pathway activation in antigen challenge of upper respiratory airways. Am Rev Respir Dis 1989, 140: 142-7.
10. Shirasaki, H., Asakura, K. Detection of platelet-activating factor in nasal lavage fluid from patients with pollinosis and experimental animals with nasal allergy. Nippon Jibiinkoka Gakkai Kaiko 1990, 93: 420-7.
11. Slater, J.W., Zechnich, A.D., Haxby, D.G. Second generation antihistamines: A comparative review. Drugs 1999, 57: 31-47.
12. Gibbs, B.F., Vollrath, I.B., Albrecht, C., Amon, U., Wolff, H.H. Inhibition of interleukin-4 and interleukin-13 release from immunologically activated human basophils due to the actions of anti-allergic drugs. Naunyn Schmiedebergs Arch Pharmacol 1998, 357: 573-8.
13. Baroody, F.M., Naclerio, R.M. Antiallergic effects of HI-receptor antagonists. Allergy 2000, 55 (Suppl. 64): 17-77.
14. Taniguchi, K., Takanaka, K. Inhibitions of metabolic responses of polymorphonuclear leukocytes by antiallergic drugs. J Pharmacobiodyn 1989, 12: 37-42.
15. Horak, F. Clinical advantages of dual activity in allergic rhinitis. Allergy 2000; 55 (Suppl. 64): 34-9.
16. Carceller, E., Merlos, M., Giral, M. et al. [(3-Pyridylalkyl)piperidylidene]benzocycloheptapyridine derivatives as dual antagonists of PAF and histamine. J Med Chem 1994, 37: 2697-703.
17. Merlos, M., Giral, M., Balsa, D. et al. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet activating factor (PAF). J Pharmacol Exp Ther 1997, 280: 114-21.
18. Queralt, M., Brazis, P., Merlos, M., de Mora, F., Puigdemont, A. In vitro inhibitory effect of rupatadine on histamine and TNF-α release from dispersed canine skin mast cells and the human cell line HMC-1. Inflam Res 2000, 49: 355-60.
19. Huther, K.J., Renftle, G., Barrand, N., Burke, J.T., Kich-Weser, J. Inhibitory activity of terfenadine on histamine-induced skin wheals in man. Eur J Clin Pharmacol 1977, 12: 195-9.
20. Bateman, D.N., Chapman, P.H., Rawlins, M.D. The effects of astemizole on histamine-induced weal and flare. Eur J Clin Pharmacol 1983, 25: 547-51.
21. García-Gea, C., Barbanoj, M.J., Morte, A. et al. Peripheral antiH1 and central nervous system activity of single increasing oral doses of rupatadine fumarate. Meth Find Exp Clin Pharmacol 1997, 19 (Suppl. A): 203 Abstr. PB-86.
22. Izquierdo, I., Nieto, C., Ramis, J., Cooper, M., Dewland, P., Forn, J. Pharmacokinetic and dose linearity of rupatadine fumarate in healthy volunteers. Meth Find Exp Clin Pharmacol 1997, 19 (Suppl. A): 189 Abstr. PB-62.
23. Queralt, M., Merlos, M., Giral, M., Puigdemont, A. Dual effect of rupatadine on edema induced by PAF and histamine in dogs: Comparison with antihistamines and PAF antagonists. Drug Develop Res 1996, 39: 12-8.
24. Merlos, M., Balsa, D., Giral, M., Ferrando, R., García-Rafanell, J., Forn, J. Inhibition of rat peritoneal mast cell exocytosis by rupatadine fumarate: A study with different secretagogues. Meth Find Exp Clin Pharmacol 1997, 19 (Suppl. A): 148.
25. Merlos, M., Ferrando, IR., Giral, M., Ramis, I., Forn, J. Effect of rupatadine in experimental conjuntivitis in guinea pigs: Macroscopic evaluation of ocular lesions. J Allergy Clin Immunol 2001, 107: S310.
26. Queralt, M., Brazis, P., Merlos, M., Puigdemont, A. Inhibitory effects of rupatadine on mast cell histamine release and skin wheal development induced by Ascaris suum, in hypersensitive dogs. Drug Develop Res 1998, 44: 49-55.
27. Queralt, M., Brazis, P., Merlos, M., Puigdemont, A. Antiallergic effect of a new compound, rupatadine, on edema induced by Ascaris suum in hypersensitive dogs: Comparison with H1-antihistamines. 3rd World Congress on Veterinary Dermatology, Edimburgh 1996.
28. Merlos, M., Ramis, I., Balsa, D., Queralt, M., Brazís, P., Pugidemont, A. Inhibitory effect of rupatadine on TNF-α release from human monocytes and mast cells line HMC-1. J Allergy Clin Immunol 2000, 105 (1, part. 2): S62.
29. Merlos, M., Balsa, D., Giral, M., Ferrando, R., García-Rafanell, J., Forn, J. Rupatadine inhibits the eosinophil recruitment in BAL fluid of ovalbumin-sensitized guinea pigs. J Allergy Clin Immunol 1998, 101 (1, part. 2): S218.
30. Merlos, M., Balsa, D., Giral, M., García-Rafanell, J., Forn, J. Antiallergic properties of UR-12592, a dual antihistamine and PAF antagonist. XV International Congress of Allergology and Clinical Inmunology, Stockholm 1994.
31. Giral, M., Balsa, D., Ferrando, R., Merlos, M., García-Rafanell, J., Forn, J. CNS activity profile of rupatadine fumarate, a new dual receptor antagonist of platelet-activating factor (PAF) and histamine. Allergy 1998, 53 (Suppl.): P321.
32. Barbanoj, M.J., Garcfa-Gea, C., Morte, A. et al. Interactions between alcohol and rupatadine examined in humans. 7th World Conf Clin Pharmacol Ther IUPHAR & 4th Cong Eur Assoc Clin Pharmacol Ther-CPT 2000, July 15-20, Florence 2000, Abstr. 825.
33. Dolovich, J., Moote, D.W., Mazza, J.A., Clemont, A., PetitClerc, C., Danzing, M. Efficacy of loratadine versus placebo in the prophylactic treatment of seasonal allergic rinitis. Ann Allergy 1994, 73: 235-9.
34. Bronsky, E., Boggs, P., Findlay, S. et al. Comparative efficacy and safety of a once daily loratadine-pseudoefedrine combination versus its components alone and placebo in the management of seasonal allergic rhinitis. J Allergy Clin Inmunol 1995, 96: 139-47.
35. Jobst, S., van den Wijngaart, W., Schubert, A., van de Venne, H. Assessment of the efficacy and safety of three dose levels of cetirizine given once daily in children with perennial allergic rhinitis. Allergy 1994, 49: 598-604.
36. Izquierdo, I., Paredes, I., Lurigados, C., Sospedra, E., Cooper, M. Thomas, H. A dose ranging study of rupatadine fumarate in patients with seasonal allergic rhinitis. Allergy 2000, 55 (Suppl. 63): 275.
37. Marti Guadaño, E., Serra-Batlles, J., Meseguer, J., Castillo, J.A., De Molina, M., Valero, A., Picado, C. Rupatadine 10 mg and ebastine 10 mg on the effect of seasonal allergic rhinitis. A double-blind, randomised, placebo-controlled trial. (summited for publication).
38. Izquierdo, I., Lurigados, C., Pérez, I., Forn, J. Rupatadine exhibits a better profile than ebastine in patients with seasonal allergic rhinitis. Allergy 2001, 56 (Suppl. 68): 200 Abstr. 635.
39. Saint Martin, F., Dumur, J.P., Pérez, I., Izquierdo, I. A randomized, double blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), anew PAF and H1 receptor-specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic-rhinitis. J Invest Allergology Clin Immunol 2003 (in press).
40. Pérez, I., Villa, M., De la Cruz, G., Izquierdo, I. Rupatadine in allergic rhinitis: Pooled analysis of efficacy data. Allergy 2002, 57 (Suppl. 73): 245 Abstr. 784.
41. Spaeth, J., Klimek, L., Mösges, R. Sedation in allergic rhinitis is caused by the condition and not by antihistamine treatment. Ann Allergy 1996, 51: 893-906.
42. CPMP Working Party on Safety of Medicinal Products. Note for guidance: "The assesment of the potential for QT interval prolongation by non-cardiovascular medicinal products". CPMP/ 986/96 London, 17 December 1997.
43. Lindquist, M., Edwards, I.R. Risks of non-sedating antihistamines. Lancet 1997; 349: 1322.
44. Rankin, A.C. Non-sedating antihistamines and cardiac arrhythmia. Lancet 1997, 350: 115-116.
45. Cohen, A.T. Dangers of non-sedating antihistamines. Lancet 1997, 350: 69.
46. Moss, A.J., Morganroth, J. Cardiac effects of ebastina and other antihistamines in humans. Drug Safety 1999, 21 (Suppl. 1): 69-80.
47. Giral, M., Merlos, M., Balsa, D., Ferrando, R., García-Rafanell, J., Forn, J. Effects of rupatadine on cardiovascular profile in rats and guinea pigs. Comparison with other nonsedating antihistamines. Allergy 1997, 52 (Suppl. 37): 044.
48. Ramis, I., Giral, M., Nieto, C., Martel, E., Merlos, M. Lack of cardiotoxic effects of rupatadine in isolated Purkinje fibres and its relationship with rupatadine cardiac levels. Allergy 2000, 55 (Suppl. 63): 264.
49. Izquierdo, I., Pérez, I., Villa, M., Giral, M., Merlos, M., Forn, J. Lack of electrocardiographic effects of rupatadine, new nonsedating selective histamine H1-receptor and PAF antagonist. Allergy 2001, 56 (Suppl. 68): 200.
50. Puddu, P., Jouve, R., Mariotti, S. et al. Evaluation of 10 QT prediction formulas in 881 middle-aged men from the seven countries study: Emphasis on the cubic root Fridericia's equation. J Electrocardiol 1988, 21: 219-29.